Pediatric Exclusivity Incentive May Encourage Sloppy Trials, FDA Says

The quality of pediatric research on antidepressants may have been affected by the need for manufacturers to complete trials in time to receive exclusivity extensions, FDA Office of Drug Evaluation I Acting Director Robert Temple, MD, suggested during the Sept. 13-14 advisory committee review of antidepressant safety